Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference
Design Therapeutics (NASDAQ: DSGN), a clinical-stage biotech company focused on developing treatments for serious degenerative genetic diseases, has announced its participation in the 2025 RBC Capital Markets Healthcare Conference. The company's management will engage in a fireside chat on Tuesday, May 20, 2025, at 8:00 a.m. ET in New York. Investors and interested parties can access the live webcast through the company's website at www.designtx.com, where it will remain archived for at least 30 days after the presentation.
Design Therapeutics (NASDAQ: DSGN), un'azienda biotecnologica in fase clinica specializzata nello sviluppo di terapie per gravi malattie genetiche degenerative, ha annunciato la sua partecipazione alla 2025 RBC Capital Markets Healthcare Conference. Il management dell'azienda parteciperà a un incontro informale il martedì 20 maggio 2025 alle 8:00 ET a New York. Investitori e interessati potranno seguire la diretta streaming sul sito web dell'azienda www.designtx.com, dove sarà disponibile in archivio per almeno 30 giorni dopo la presentazione.
Design Therapeutics (NASDAQ: DSGN), una empresa biotecnológica en fase clínica enfocada en desarrollar tratamientos para enfermedades genéticas degenerativas graves, ha anunciado su participación en la Conferencia de Salud de RBC Capital Markets 2025. La dirección de la compañía participará en una charla informal el martes 20 de mayo de 2025 a las 8:00 a.m. ET en Nueva York. Inversores e interesados podrán acceder a la transmisión en vivo a través del sitio web de la empresa www.designtx.com, donde estará archivada por al menos 30 días después de la presentación.
Design Therapeutics (NASDAQ: DSGN)는 심각한 퇴행성 유전 질환 치료제 개발에 주력하는 임상 단계 바이오텍 기업으로, 2025년 RBC Capital Markets 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사 경영진은 2025년 5월 20일 화요일 오전 8시(동부시간) 뉴욕에서 진행되는 비공식 대화에 참석할 예정입니다. 투자자 및 관심 있는 분들은 회사 웹사이트 www.designtx.com을 통해 생중계에 접속할 수 있으며, 발표 후 최소 30일간 아카이브로 제공됩니다.
Design Therapeutics (NASDAQ : DSGN), une société biotechnologique en phase clinique spécialisée dans le développement de traitements pour des maladies génétiques dégénératives graves, a annoncé sa participation à la conférence RBC Capital Markets Healthcare 2025. La direction de l'entreprise participera à une discussion informelle le mardi 20 mai 2025 à 8h00 (heure de l'Est) à New York. Les investisseurs et les parties intéressées pourront accéder à la diffusion en direct via le site web de la société www.designtx.com, où elle restera archivée pendant au moins 30 jours après la présentation.
Design Therapeutics (NASDAQ: DSGN), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Behandlungen für schwere degenerative genetische Erkrankungen spezialisiert hat, hat seine Teilnahme an der 2025 RBC Capital Markets Healthcare Conference angekündigt. Das Management des Unternehmens wird am Dienstag, den 20. Mai 2025, um 8:00 Uhr ET in New York an einem informellen Gespräch teilnehmen. Investoren und Interessierte können den Live-Webcast über die Website des Unternehmens www.designtx.com verfolgen, wo er mindestens 30 Tage nach der Präsentation archiviert bleibt.
- None.
- None.
CARLSBAD, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat during the 2025 RBC Capital Markets Healthcare Conference on Tuesday, May 20, 2025, at 8:00 a.m. ET in New York.
A live webcast of the fireside chat will be available here and in the investors section of the company’s website at www.designtx.com. The webcast will be archived for at least 30 days following the presentation.
About Design Therapeutics
Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC® gene targeted chimera small molecules. The company’s GeneTAC® molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its clinical-stage GeneTAC® programs, DT-216P2, in development for patients with Friedreich ataxia, and DT-168, for Fuchs endothelial corneal dystrophy, the company is advancing programs in myotonic dystrophy type-1 and Huntington’s disease. Discovery efforts are underway for multiple genomic medicines. For more information, please visit designtx.com.
Contact:
Renee Leck
THRUST Strategic Communications
renee@thrustsc.com
FAQ
When is Design Therapeutics (DSGN) presenting at the 2025 RBC Capital Markets Healthcare Conference?
Where can I watch Design Therapeutics' (DSGN) presentation at the RBC Healthcare Conference?
How long will Design Therapeutics' (DSGN) RBC Conference presentation be available to view?
What type of company is Design Therapeutics (DSGN)?
